Significance StatementClinical outcome of cord blood transplantation transplanted with human leukocyte antigen (HLA) homozygous haplotype (HP) yielded a number of important implications, namely the possibility of favorable engraftment in HLA homo induced pluripotent stem cells (iPS) transplantation and detailed information of HLA alleles and haplotypes of HLA‐homozygous HPs. Accumulation of such immunological genetic data for established HLA‐homo iPSs and for pairs in upcoming clinical iPS transplantation is essential to ensuring the safety and consistent success of iPS transplantation.

Introduction {#sct312270-sec-0002}
============

Induced pluripotent stem cells (iPS), prepared by the introduction of four specific genes encoding the transcription factors Oct4, Sox2, Klt4, and c‐Myc, have the capacity to generate various tissues/organs [1](#sct312270-bib-0001){ref-type="ref"}. Clinical application in autologous settings in humans has just begun, such as in retinal regeneration [2](#sct312270-bib-0002){ref-type="ref"}, [3](#sct312270-bib-0003){ref-type="ref"}, [4](#sct312270-bib-0004){ref-type="ref"}, [5](#sct312270-bib-0005){ref-type="ref"}. However, autologous transplantation is hampered by the high time and cost required for the individual production of iPS. To solve these issues, allogeneic iPS transplantation from iPS banking has been proposed [6](#sct312270-bib-0006){ref-type="ref"}, [7](#sct312270-bib-0007){ref-type="ref"}. One candidate for this is iPS induced from individuals with a homozygous human leucocyte antigen (HLA) haplotype (HLA‐homo) [8](#sct312270-bib-0008){ref-type="ref"}, [9](#sct312270-bib-0009){ref-type="ref"}, [10](#sct312270-bib-0010){ref-type="ref"}, on the basis that HLA‐homo iPS might not be rejected by HLA haplotype‐matched patients. At present, HLA‐homo volunteer donors in Japan are recruited from among donors with available HLA data in HLA‐matched platelet transfusion registries, bone marrow donor registries, and cord blood banks.

However, concerns have been raised over whether allogeneic iPS transplantation from HLA‐homo iPS induces immunogenicity in clinical settings [11](#sct312270-bib-0011){ref-type="ref"}, [12](#sct312270-bib-0012){ref-type="ref"}, [13](#sct312270-bib-0013){ref-type="ref"}. In vitro assay and animal model studies to experimentally verify the risk of HLA‐homo iPS transplantation have been extensively reported. Among these, Sugita et al. showed a lack of T cell response by iPSC‐derived retinal pigment epithelial cells [14](#sct312270-bib-0014){ref-type="ref"}; Suzuki et al. showed natural killer cell activity against iPS‐derived HLA‐knockout megakaryocytes [15](#sct312270-bib-0015){ref-type="ref"}; Mizukami et al. analyzed immune response in pigs [16](#sct312270-bib-0016){ref-type="ref"}, and Sun et al. showed the insensitivity of human iPS in a hind limb ischemia mouse model [17](#sct312270-bib-0017){ref-type="ref"}. To date, however, no clinical data assessing the immunological reactivity of allogeneic iPS transplantation have yet been reported.

Allogeneic hematopoietic stem cell transplantation (HSCT) is characterized as the regenerative transplantation of hematopoietic progenitor cells, and has yielded practical clinical applications for the last 50 years [18](#sct312270-bib-0018){ref-type="ref"}. HSCT, especially cord blood transplantation (CBT) [19](#sct312270-bib-0019){ref-type="ref"}, [20](#sct312270-bib-0020){ref-type="ref"}, might be a suitable model for evaluating the allogeneic immunogenicity of iPS transplantation from HLA‐homo donors. HLA mismatch CBT from donors with less than two HLA loci mismatches is common but carries a high engraftment failure rate, with a range of 10% to 20%. Further, cord blood cells are reported to be good source for the production of iPS [21](#sct312270-bib-0021){ref-type="ref"}, [22](#sct312270-bib-0022){ref-type="ref"}, [23](#sct312270-bib-0023){ref-type="ref"}, [24](#sct312270-bib-0024){ref-type="ref"}, [25](#sct312270-bib-0025){ref-type="ref"}.

Here, as part of our efforts to improve HLA‐homo iPS banking and transplantation, we report an analysis of allogeneic immunogenicity which focuses on engraftment of unrelated transplantation from HLA‐homo cord blood.

Materials and Methods {#sct312270-sec-0003}
=====================

Study Population {#sct312270-sec-0004}
----------------

This analysis examined cord blood transplant pairs (*n* = 1,374) obtained from the collected samples of seven cord blood banks in Japan. To be included in the analysis, samples had to meet the following criteria: (a) transplantation pairs retyped for HLA‐A, ‐B, and ‐DRB1 alleles and newly typed for HLA‐C, ‐DQB1, and ‐DPB1 alleles, as described below; (b) first transplantation; (c) single‐unit cord blood; (d) HLA‐A, ‐B, and ‐DRB1 antigen level matching within 2 mismatches, which is the standard criterion for cord blood donor selection in Japan; (e) no use of anti‐thymocyte globulin for graft‐versus‐host disease (GVHD) prophylaxis; (f) Japanese pairs; and (g) survival for more than 7 days after transplantation. Patient and transplant characteristics are shown in Table [3](#sct312270-tbl-0003){ref-type="table-wrap"}. Patient age ranged from 0 to 88 years (median 44). Disease status and classification of patients at the time of transplantation were as follows. Standard‐risk leukemia was defined as acute myeloblastic leukemia in the first or second complete remission (CR), acute lymphoblastic leukemia in the first CR, chronic myelocytic leukemia in the first chronic phase, and myelodysplastic syndrome in refractory anemia or in refractory anemia with ringed sideroblasts. High‐risk leukemia was defined as transplantation at a more advanced stage than with standard‐risk leukemia.

All cord bloods were selected through the Japan Cord Blood Bank Network [22](#sct312270-bib-0022){ref-type="ref"}. The final clinical survey of patients was completed by 2013, and informed consent was obtained from patients and donors in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Aichi Cancer Center and each participating cord blood bank.

Outcome Definition {#sct312270-sec-0005}
------------------

Neutrophil engraftment was defined as more than 500 cells per μl in peripheral blood at three consecutive measurements within 100 days after transplantation. Platelet engraftment was defined as more than 50,000 cells per μl without transfusion support. Mortality was defined as death from any causes that occurred after the day of transplantation. Clinical grading of acute GVHD was performed according to established criteria [23](#sct312270-bib-0023){ref-type="ref"}.

HLA Typing and the Definition of HLA Homozygosity {#sct312270-sec-0006}
-------------------------------------------------

All donor‐patient pairs were retrospectively genotyped at the Japanese Red Cross Kanto‐Koshinetsu Block Blood Center for HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1, and ‐DPB1 alleles at the field 1 and field 2 level of the 2010 World Health Organization Nomenclature for factors for the HLA system [26](#sct312270-bib-0026){ref-type="ref"}. All samples were examined using the PCR‐SSO method, with the PCR‐SBT method used to confirm any rare or new alleles. An HLA‐locus mismatch in the GVH direction among the donor‐recipient pairs was scored when the recipient\'s HLA alleles were not shared by the donor, while an HLA‐locus mismatch in the HVG direction was scored when the donor\'s HLA alleles were not shared by the recipient.

HLA homozygosity of HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 in allele level was defined when only one allele was observed in each of these five HLA loci, and HLA heterozygosity was defined when two alleles were observed in any of these loci. The combination of donor HLA homozygote (homo) and patient HLA heterozygote (hetero) was simplified as homo‐hetero; donor hetero and patient homo as hetero‐homo; donor homo and patient homo as homo‐homo; and donor hetero and patient hetero as hetero‐hetero. Hetero‐hetero combination was further subdivided into three groups by the number of HLA‐A, ‐B, and ‐C mismatched loci in the HVG direction at the allele level, namely hetero‐hetero (0) and hetero‐hetero (1--2) and (3). As the risk of mismatch of HLA‐DRB1, ‐DQB1, and ‐DPB1 was not observed (Supporting Information Table 2), HLA‐A, ‐B, and ‐C matching was selected for analysis of the number of HLA locus mismatches, and the risk of the number of HLA‐A, ‐B, and ‐C mismatches is shown in Supporting Information Table 3. As the risk of 1 locus mismatch and 2 loci mismatch had the same hazard ratio of 0.76, 1, and 2 locus mismatches were lumped together. KIR2DL ligand specificity of HLA‐C antigen was determined according to the HLA‐C allele. The epitope of HLA‐Cw3 group (C1 specificity) consists of Asn80, and that of the HLA‐Cw4 group (C2 specificity) consists of Lys80. KIR ligand mismatch in the GVH direction was scored when the donor KIR2DL epitope of HLA‐C was not shared by the patient epitope. This mismatch occurred when KIR2DL2/3‐ or KIR2DL1‐positive effector cells were activated without expression of the corresponding HLA‐C ligand (C1 or C2, respectively), on the patient target cells. KIR ligand mismatch in the HVG direction was scored when the patient KIR2DL epitope of HLA‐C was not shared by the donor. This mismatch occurred when patient KIR2DL2/3‐ or KIR2DL1‐positive effector cells were activated without expression of the corresponding HLA‐C ligand (C1 or C2, respectively) on donor cells.

Statistical Analysis {#sct312270-sec-0007}
--------------------

The hazard ratio of neutrophil engraftment was assessed using multivariable competing risk regression analysis [27](#sct312270-bib-0027){ref-type="ref"}. Potential confounders considered in the multivariate study were transfused mononuclear cell number per patient weight (kg), patient age (linear), disease, disease stage (standard or high risk), GVHD prophylaxis (cyclosporine‐based, tacrolimus‐based, or other regimen), conditioning regimen (myeloablative or non‐myeloablative/reduced intensity), and period of transplantation. Impact by the factor of interest was assessed using the log‐rank test, and impact on overall survival was evaluated using Cox\'s proportional hazards regression model [26](#sct312270-bib-0026){ref-type="ref"}. The cumulative incidence curve of engraftment was assessed using the competing risk regression method adjusted with the confounders described above. Overall survival was calculated using the Kaplan‐Meier method. All outcomes were assessed in patients who survived more than 7 days after transplantation. We assessed acute GVHD, neutrophil engraftment, and platelet engraftment at 100 days. *p* values of less than .05 were considered significant. All analyses were conducted using STATA version 12 (Stata Corp.; College Station, TX).

Results {#sct312270-sec-0008}
=======

Clinical Outcome of Donor HLA‐Homo and Patient HLA‐Hetero Pairs {#sct312270-sec-0009}
---------------------------------------------------------------

Six pairs with donor HLA homo‐patient HLA hetero (homo‐hetero) were found, all of which showed favorable neutrophil engraftment between 15 and 30 days after transplantation (Table [1](#sct312270-tbl-0001){ref-type="table-wrap"}). Platelets were engrafted in all 4 patients, excluding 2 patients with early death, and no secondary engraftment failure (rejection) occurred in any pair. Grade III and grade II acute GVHD did occur in pair no. 2 and 3, respectively, while no acute GVHD was seen in the other four pairs (Table [1](#sct312270-tbl-0001){ref-type="table-wrap"}).

###### 

Clinical data of donor HLA‐homo and patient HLA‐hetero pairs

  No.   Disease   Leukemia risk   Patient age (y.o.)   TNC/kg[a](#sct312270-note-0004){ref-type="fn"} (×10^7^)   Neutrophil eng.[b](#sct312270-note-0005){ref-type="fn"} (days)   Platelet eng.[c](#sct312270-note-0006){ref-type="fn"} (days)   Acute GVHD (grade)   Alive/Dead (days)
  ----- --------- --------------- -------------------- --------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------- -------------------- -------------------
  1     AML       High            66                   4.27                                                      Y (25)                                                           N (43)                                                         0                    Dead (43)
  2     ALL       High            62                   3.19                                                      Y (17)                                                           N (41)                                                         III                  Dead (41)
  3     AML       Standard        60                   3.88                                                      Y (15)                                                           Y (41)                                                         II                   Alive (726)
  4     CML       High            37                   3.11                                                      Y (23)                                                           Y (51)                                                         0                    Alive (1,250)
  5     MDS       Standard        47                   2.92                                                      Y (20)                                                           Y (75)                                                         0                    Alive (1,455)
  6     MDS       High            66                   2.50                                                      Y (30)                                                           Y (101)                                                        0                    Dead (400)

Abbreviations: AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelocytic leukemia; MDS, myelodysplastic syndrome.

Total nuclear cell number of cord blood per patient\'s weight (kg).

Y: Engraftment of neutrophil. Days of neutrophil number reached to 500/microliter.

Y: Engraftment of platelet. Days of platelet number reached to 50,000/microliter.

HLA Haplotype and Alleles in Donor HLA‐Homo and Patient HLA‐Hetero Combination {#sct312270-sec-0010}
------------------------------------------------------------------------------

Donor and patient HLA alleles and HLA haplotypes are shown in Table [2](#sct312270-tbl-0002){ref-type="table-wrap"}. Patient HLA alleles not shared with the donor are in bold character style. All 6 pairs had the common haplotypes (HP‐1, 3 pairs; HP‐2, 2 pairs; and HP‐3, 1 pair). Five donor HPs, but not pair no. 5, had the same HLA‐DPB1 allele, consistent with reports that these common HLA‐HP show a long‐stretch homogeneous region from HLA‐A to HLA‐DPB1 [28](#sct312270-bib-0028){ref-type="ref"}. HPs with high to low frequency were found in patient non‐shared HPs, some of which showed the possibility of recombination between HLA loci, such as no. 1 and no. 4.

###### 

HLA haplotype and its alleles in donor HLA‐homo and patient HLA‐hetero pairs

                HLA‐haplotype[a](#sct312270-note-0008){ref-type="fn"}   A                C                 B                 DRB1[a](#sct312270-note-0008){ref-type="fn"}   DQB1              DPB1[a](#sct312270-note-0008){ref-type="fn"}
  --- --------- ------------------------------------------------------- ---------------- ----------------- ----------------- ---------------------------------------------- ----------------- ----------------------------------------------
  1   Donor     HP‐1                                                    24:02            12:02             52:01             15:02                                          06:01             09:01
      Patient   HP‐1/HP‐16                                              24:02            12:02             52:01             15:02/**09:01**                                06:01/**0303**    09:01/**0501**
  2   Donor     HP‐1                                                    24:02            12:02             52:01             15:02                                          06:01             09:01
      Patient   HP‐1/HP‐3                                               24:02            12:02/**07:02**   52:01/**07:02**   15:02/**0101**                                 06:01/**0501**    09:01/**0402**
  3   Donor     HP‐1                                                    24:02            12:02             52:01             15:02                                          06:01             09:01
      Patient   HP‐1/HP‐136                                             24:02            12:02/**07:02**   52:01/**40:01**   15:02/**08:03**                                06:01             09:01/**02:01**
  4   Donor     HP‐2                                                    33:03            14:03             44:03             13:02                                          06:04             04:01
      Patient   HP‐2/HP‐X                                               33:03/**0201**   14:03             44:03             13:02                                          06:04             04:01
  5   Donor     HP‐2                                                    33:03            14:03             44:03             13:02                                          06:04             04:01/**06:01**
      Patient   HP‐2/HP‐Y                                               33:03            14:03/**07:02**   44:03/**39:02**   13:02/**0901**                                 06:04/**03:03**   04:01/**02:01**
  6   Donor     HP‐3                                                    24:02            07:02             07:02             01:01                                          05:01             04:02
      Patient   HP‐3/HP‐Z                                               24:02            07:02/**14:02**   07:02**/51:01**   01:01/**04:04**                                05:01/**04:02**   04:02/**02:01**

Patient HLA alleles not shared with the donor are in bold character style.

Numbered individual haplotypes in order of frequency. X, Y, and Z indicate nongrouped rare haplotypes.

The KIR2DL1 epitope was donor C1/C1 and patient C1/C1 in all six pairs, making the KIR2DL ligand match combination in both the HVG and GVH vectors.

Statistical Analysis for Risk of Neutrophil Engraftment by HLA Homozygosity {#sct312270-sec-0011}
---------------------------------------------------------------------------

Combinations of HLA‐homo and HLA‐hetero between cord blood and patient were grouped. The hetero‐hetero group was further subdivided according to the number of HLA‐A, ‐B, and ‐C mismatch loci in the HVG direction at the allele level, and analyzed by competing risk regression analysis with adjustment for other cofounders, as listed in the Materials and Methods section above.

These six donor homo‐patient hetero (homo‐hetero) pairs revealed significantly higher engraftment risk (HR = 1.59) than the hetero‐hetero group with HLA 1--2 mismatch (789 pts) (*p* = .047) (Table [3](#sct312270-tbl-0003){ref-type="table-wrap"}), and tended to show a comparatively higher risk (HR = 1.23) than hetero‐hetero with 0 mismatches (104 pts) (*p* = .337) (Supporting Information Table 1). The competing risk regression curve of neutrophil engraftment is shown in Figure [1](#sct312270-fig-0001){ref-type="fig"}. These data indicated that HLA‐homo cord blood produced favorable engraftment.

![Neutrophil engraftment curve by the combination of HLA‐haplotypes. Cumulative incidence curve was assessed using the competing risk regression method with adjustment for the confounders described in Table [3](#sct312270-tbl-0003){ref-type="table-wrap"}. Homo‐hetero, combination of donor with HLA‐homo and patient with HLA‐hetero; hetero‐hetero (1--2), combination of donor with HLA‐hetero and patient with HLA‐hetero and 1 or 2 locus mismatches in HLA‐A, ‐B, and ‐C loci at the allele level. The other lines are described in detail in the Materials and Methods section.](SCT3-7-173-g001){#sct312270-fig-0001}

###### 

Statistical analysis for risk of neutrophil engraftment by HLA homozygosity and other clinical variables

  Variable                                                                          Patient no.   Hazard ratio   \[95% conf. Interval\]   *p* value
  --------------------------------------------------------------------------------- ------------- -------------- ------------------------ -----------
  HLA matching (HLA mismatch locus[a](#sct312270-note-0002){ref-type="fn"} *no.)*                                                         
  hetero‐hetero (1--2)                                                              789           1.00                                    
  hetero‐hetero (3)                                                                 455           0.85           0.75--0.97               .016
  hetero‐hetero (0)                                                                 104           1.25           1.00--1.55               .047
  homo‐hetero                                                                       6             1.59           1.00--2.54               .049
  hetero‐homo                                                                       13            0.50           0.24--1.03               .062
  homo‐homo                                                                         7             1.21           0.51--2.88               .660
  Transfused nuclear cell no./weight (kg) × 10**^*7*^**                                                                                   
  \< 3.0                                                                            851           1.00                                    
  3.0≤--5.0\<                                                                       371           1.20           1.05--1.37               .007
  5≤                                                                                124           1.68           1.34--2.12               \<.001
  Unknown                                                                           28            1.29           0.78--2.14               .328
  Patient age, yrs, median (range): 44 (0--88)                                                                                            
  linear                                                                            1,374         1.00001        0.996--1.004             .996
  Disease                                                                                                                                 
  AML                                                                               272           1.00                                    
  ALL                                                                               664           0.82           0.71--0.96               .012
  MDS                                                                               148           0.83           0.67--1.03               .097
  Others                                                                            290           0.85           0.69--1.04               .113
  Transplanted year                                                                                                                       
  1999--2006                                                                        398           1.00                                    
  2007--2009                                                                        581           1.14           0.99--1.31               .069
  2010--2012                                                                        395           1.26           1.06--1.49               .008
  GVHD prophlaxis                                                                                                                         
  Cyclosporine based                                                                574           1.00                                    
  Tacroliumus based                                                                 787           1.04           0.92--1.17               .537
  Others                                                                            13            0.75           0.34--1.62               .461
  Disease stage                                                                                                                           
  Standard risk                                                                     470           1.00                                    
  High risk                                                                         769           0.78           0.69--0.89               \<.001
  Others                                                                            135           0.83           0.64--1.09               .182
  Conditioning                                                                                                                            
  Non‐myeloablative                                                                 457           1.00                                    
  Myeloablative                                                                     619           0.85           0.73--0.99               .033
  Unknown                                                                           298           0.82           0.68--0.98               .030

Homo‐hetero: combination of donor with HLA‐homo and patient with HLA‐hetero. hetero‐hetero (1--2): combination of donor with HLA‐hetero and patient with HLA‐hetero and 1 or 2 locus mismatches in HLA‐A, ‐B, and ‐C loci at the allele level.Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; GVHD, graft‐versus‐host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome.

HLA‐A, ‐B and ‐C locus mismatch in HVG direction.

The donor hetero‐patient homo group (hetero‐homo) consisted of 13 patients, who revealed a tendency to a lower engraftment ratio (HR = 0.50) than the hetero‐hetero group with HLA 1--2 mismatch (789 pts) (*p* = .062) (Table [3](#sct312270-tbl-0003){ref-type="table-wrap"})

With hetero‐hetero combination, the risk of engraftment decreased as the number of HLA mismatch loci in HLA‐A, ‐B, and ‐C increased (Table [3](#sct312270-tbl-0003){ref-type="table-wrap"}).

Risk of variables other than HLA are also listed in Table [3](#sct312270-tbl-0003){ref-type="table-wrap"}. Transplanted nuclear cell number per patient weight, disease, transplanted year, disease stage, and conditioning regimen were found to be significant factors.

Statistical Analysis for Risk of Mortality by HLA Homozygosity {#sct312270-sec-0012}
--------------------------------------------------------------

The six donor homo‐patient hetero (homo‐hetero) pairs revealed no significant mortality risk (HR = 0.81) compared with the hetero‐hetero group with HLA 1--2 mismatch (817 pts) (*p* = .72) (Table [4](#sct312270-tbl-0004){ref-type="table-wrap"}), or mortality risk (HR = 0.85) compared with hetero‐hetero with 0 mismatches (108 pts) (*p* = .72) (Supporting Information Table 4). The Kaplan‐Meier curve of mortality is shown in Supporting Information Figure 1.

###### 

Statistical analysis for the risk of mortality by HLA homozygosity and other clinical variables

  Variable                                                                        Patient no.   Hazard ratio   \[95% conf. Interval\]   *p* value
  ------------------------------------------------------------------------------- ------------- -------------- ------------------------ -----------
  HLA matching (HLA mismatch locus[a](#sct312270-note-0010){ref-type="fn"} no.)                                                         
  hetero‐hetero (1--2)                                                            817           1.00                                    
  hetero‐hetero (3)                                                               476           1.05           0.90--1.22               .559
  hetero‐hetero (0)                                                               108           0.95           0.71--1.28               .738
  homo‐hetero                                                                     6             0.81           0.26--2.54               .72
  hetero‐homo                                                                     13            1.02           0.50--2.06               .96
  homo‐homo                                                                       7             1.79           0.66--4.85               .249
  Transfused nuclear cell no./weight (kg) × 10**^7^**                                                                                   
  3.0\<                                                                           883           1.00                                    
  3.0≥--5.0\<                                                                     386           1.20           1.02--1.41               .026
  5.0≥                                                                            125           1.17           0.83--1.64               .377
  Unknown                                                                         33            1.65           1.04--2.60               .032
  Patient age, yrs, median (range): 44 (0--88)                                                                                          
  linear                                                                          1,427         1.02           1.02--1.03               \<.001
  Disease                                                                                                                               
  AML                                                                             281           1.00                                    
  ALL                                                                             690           0.92           0.74--1.14               .450
  MDS                                                                             151           0.67           0.50--0.91               .010
  Others                                                                          305           0.77           0.58--1.03               .076
  Transplanted year                                                                                                                     
  1999--2006                                                                      424           1.00                                    
  2007--2009                                                                      604           0.76           0.64--0.91               .003
  2010--2012                                                                      399           0.84           0.68--1.04               .118
  GVHD prophlaxis                                                                                                                       
  Cyclosporine based                                                              595           1.00                                    
  Tacroliumus based                                                               813           1.01           0.88--1.18               .844
  Others                                                                          19            1.05           0.56--1.97               .887
  Disease stage                                                                                                                         
  Standard risk                                                                   483           1.00                                    
  High risk                                                                       799           2.52           2.10--3.01               \<.001
  Others                                                                          145           3.46           2.49--4.82               \<.001
  Conditioning                                                                                                                          
  Non‐myeloablative                                                               479           1.00                                    
  Myeloablative                                                                   639           0.94           0.78--1.13               .526
  Unknown                                                                         309           1.05           0.85--1.30               .620

Homo‐hetero: combination of donor with HLA‐homo and patient with HLA‐hetero. hetero‐hetero (1--2): combination of donor with HLA‐hetero and patient with HLA‐hetero and 1 or 2 locus mismatches in HLA‐A, ‐B and ‐C loci at the allele level.Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; GVHD, graft‐versus‐host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome.

HLA‐A, ‐B, and ‐C locus mismatch in HVG direction.

Discussion {#sct312270-sec-0013}
==========

In this study, we identified 6 CBT pairs with unrelated HLA‐homo cord blood to HLA‐hetero patient transplantation among 1,374 CBT pairs. All six pairs showed favorable neutrophil engraftment. Statistical analysis demonstrated a possibly compatible engraftment ratio compared with CBTs from hetero cord blood to hetero patients with HLA‐match, and a better engraftment ratio than in CBTs from hetero cord blood to hetero patients with HLA‐one locus mismatch. These findings and the HLA haplotype information carry a number of implications for HLA‐homo iPS banking and transplantation.

First, only 6 HLA‐homo individuals were identified among this large cohort of 1,374 CBT donors, and all 6 possessed common HLA haplotypes. Therefore, it is practical to recruit HLA haplotype‐homo individuals with common HLA haplotypes for iPS banking. The chance of encountering an HLA‐homo individual has been calculated in diverse populations, including Japanese [24](#sct312270-bib-0024){ref-type="ref"}, [29](#sct312270-bib-0029){ref-type="ref"}, [30](#sct312270-bib-0030){ref-type="ref"}, Chinese [31](#sct312270-bib-0031){ref-type="ref"}, British [32](#sct312270-bib-0032){ref-type="ref"}, [33](#sct312270-bib-0033){ref-type="ref"}, and Brazilian [28](#sct312270-bib-0028){ref-type="ref"}. Results showed that the chance of finding an HLA‐homo HP markedly differs among countries, and depends on the diversity of the ethnic population. Nakatsuji et al. calculated that 15,000 individuals would be required to find top 50 HLA‐homo individuals at the HLA ‐A, ‐B, and ‐DR antigen level, which covers 82.2% of the Japanese population [30](#sct312270-bib-0030){ref-type="ref"}. Okita et al. also calculated the chance of finding HLA‐homo by HLA allele level [24](#sct312270-bib-0024){ref-type="ref"}. Efforts are now underway in Japan to identify such individuals among already‐HLA‐typed donors in public cord blood banks, the Japan Marrow Donor Program, and the platelet donor registry of the Japanese Red Cross Blood Center.

Second, HPs with high frequency are considered to represent a conserved extended haplotype (CEH), and to be specific to the particular ethnic population. In the present study, HLA‐homo HPs of cord blood were most frequently the best three CEHs, namely HP‐1, HP‐2, and HP‐3, which revealed highly conserved MHC blocks through the entire HLA region, as we reported previously [28](#sct312270-bib-0028){ref-type="ref"}. The most common extended HLA haplotype in northern European populations is 8.1 HP, with HLA‐A1‐Cw3‐B8‐DR3‐DQ2 and showing remarkable conservation [34](#sct312270-bib-0034){ref-type="ref"}. These common CEHs can be distinguished from each another at many levels of genetic diversity, including coding regions of complex genes such as HLA, and noncoding forms of variation. Thus, it is important to recognize that not only alleles of classical HLA loci, such as HLA‐A, ‐B, ‐C, and ‐DRB1, but also those of other HLA genes, as well as non‐HLA genes within HLA regions and noncoding regions of these HPs, are common, either entirely or partly.

Third, one of the two patient heterogeneous HPs was invariably shared with the same HP as the cord blood HLA‐homo HP, while another non‐shared patient HP was mismatched with 1 to 4 HLA alleles among HLA‐A, ‐B, ‐C, and ‐DRB1 loci in the GVH direction. Conversely, patients possessing one common HLA haplotype have a higher chance of finding the HLA‐homo iPS.

Fourth, because all six pairs of HLA‐homo cord blood and HLA‐hetero patient were KIR2DL ligand‐matched, the risk of KIR ligand mismatch remains to be elucidated. As the frequency of the C2 epitope among Japanese is low (7%), the chance of KIR2DL ligand mismatch for HLA‐homo iPS, that is, a pair with cord C2 and patient C1C2, is rare. Among the 10 most frequent Japanese HPs, only the eighth‐most frequent HP has HLA‐C\*04:01 (C2 epitope). Nevertheless, KIR ligand mismatch should be kept in mind, given our previous report that KIR ligand mismatch in the HVG direction induces a poorer engraftment rate than match in unrelated HSCT [35](#sct312270-bib-0035){ref-type="ref"} and KIR incompatibility in the HVG direction ameliorated engraftment in ALL CBT patients [36](#sct312270-bib-0036){ref-type="ref"}. A mechanism termed "hybrid resistance" in a mouse model [37](#sct312270-bib-0037){ref-type="ref"} might be evoked in HLA‐homo iPS situations. An understanding of the expression of HLA molecules on iPS cells is important. For example, when iPS differentiate to a committed tissue progenitor cell, these cells might not express HLA‐class I molecule, making them eligible for targeting by NK cells [15](#sct312270-bib-0015){ref-type="ref"}, [16](#sct312270-bib-0016){ref-type="ref"}. HLA mismatch combination in the present six homo to hetero pairs was also found to be KIR ligand‐matched in the HLA‐A, B locus.

As the present results for CBT were obtained using immunosuppressants, including calcineurin inhibitors, the question of whether iPS transplantation requires immunosuppression to suppress the immunogenicity of HLA‐homo iPS remains unclear.

Our analysis also provides other HLA‐homozygosity results for engraftment. The wide range of hazard ratio for the seven pairs with the cord HLA‐homo and patient HLA‐homo combination failed to provide evidence. Thirteen pairs with the combination of cord HLA‐hetero and patient homo showed a significantly poorer engraftment ratio, which might have been due to HVG mismatch combination and/or possible donor specific antibodies (data not shown). With an increase in HLA locus mismatch at the allele level of HLA‐A, ‐B, and ‐C, a lower engraftment ratio was observed, confirming that the rejection mechanism in this CBT study involved HLA disparity.

Acute GVHD occurred in two of six pairs with HLA‐homo HPs, or namely mismatch combination in the GVH direction. This situation might be kept in mind when cytotoxic T cell‐iPS specific to some tissues is induced in allogeneic HLA‐homo donor settings. Engrafted cells with HLA‐homo iPS might induce hyperacute GVHD mimicking post transfusion GVHD, or induce T‐cell anergy [38](#sct312270-bib-0038){ref-type="ref"}.

Several limitations of our study warrant mention. First, the number of homo‐hetero pairs was small, which may have affected the accuracy of the results. Recruitment of more CBTs with HLA allele typing is required. Second, data were only available for the three major donor HLA‐homo HPs, and the risk of other HLA haplotypes among Japanese needs to be explored. Also, data for other ethnic populations with a more diverse HLA haplotype are lacking. Addressing this situation will require international collaboration and a very large database.

Summary {#sct312270-sec-0014}
=======

The clinical outcome of CBT with HLA‐homo HP yields a number of important implications, namely the possibility of favorable engraftment in HLA homo iPS transplantation and detailed information of HLA alleles and haplotypes of HLA‐homo HPs. Accumulation of such immunological genetic data for established HLA‐homo iPSs and for pairs in upcoming clinical iPS transplantation is essential to ensuring the safety and consistent success of iPS transplantation.
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